| 6XKR: reference: Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-Affinity Engineered Anti-Human PD-1 Antibody., Al-Khami AA, Youssef S, Abdiche Y, Nguyen H, Chou J, Kimberlin CR, Chin SM, Kamperschroer C, Jessen B, Kern B, Budimir N, Dillon CP, Xu A, Clark JD, Chou J, Kraynov E, Rajpal A, Lin JC, Salek-Ardakani S, Mol Cancer Ther. 2020 Aug 26. pii: 1535-7163.MCT-20-0093. doi:, 10.1158/1535-7163.MCT-20-0093. PMID: 32847983 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).